Durvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker Study

NCT04392505 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Cancer
Non Small Cell Lung Cancer
Non Small Cell Lung Cancer Stage III
NSCLC
NSCLC, Stage III

Interventions

DRUG: Durvalumab Injection

Sponsor

Oslo University Hospital

Collaborators

[object Object]